Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15345554 | 0.91 | GABRA1 (0.46) | LOXL2CYP2A6PNMTCSNK2A2CSNK2B | |
| SCHEMBL5682891 | 0.87 | GABRA1 (0.43) | CNR2GABRA1GABRB2TP53 | |
| SCHEMBL30537735 | 0.87 | GABRA1 (0.43) | CNR2GABRA1GABRB2TP53 | |
| SCHEMBL29463712 | 0.87 | LOXL2 (0.56) | LOXL2CYP2A6PNMTHTR2ADPP4 | |
| SCHEMBL5052533 | 0.87 | LOXL2 (0.56) | LOXL2CYP2A6PNMTHTR2ADPP4 | |
| Hydrochloric Acid SCHEMBL5691546 | 0.85 | LOXL2 (0.54) | LOXL2CYP2A6PNMTHTR2ADPP4 | |
| SCHEMBL19248498 | 0.82 | TAAR1 (0.48) | CYP2A6HTR2AHTR6 | |
| SCHEMBL29352142 | 0.80 | CNR2 (0.39) | CNR2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL31574390 | 0.79 | IDO1 (0.47) | CNR2 | |
| SCHEMBL3914647 | 0.79 | CYP1A2 (0.59) | LOXL2CYP2A6PNMTHTR2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093939-A9 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170233325-A1 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
| EP-2657214-B1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL CO (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8993774-B2 | Process for production of aromatic alcohol or heterocyclic aromatic alcohol | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-11-14 | — | — | US | disclosed |
| EP-2657214-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | Mitsubishi Gas Chemical Company, Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093939-A9 | NOVEL MONOMERS FROM BIOMASS | DCXR, MANBA, PGLS | LOXL2 458/4885CYP2A6 4532/4885PNMT 1782/4885 |
| US-20170233325-A1 | NOVEL MONOMERS FROM BIOMASS | DCXR, MANBA, PGLS | LOXL2 458/4885CYP2A6 4532/4885PNMT 1782/4885 |
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | ADH1C, ADH1A, ADH5 | LOXL2 3456/4885CYP2A6 278/4885PNMT 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.